Market research
OPGN OpGen Inc
PINK USD Financial Services
Latest close
As of 07 Jun 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 251M
- P/E ratio
- 137.5
- Analyst target
- 3
- Dividend yield
- Not available
- Beta
- -3052.63
Profile
Instrument facts
- Exchange
- PINK
- Currency
- USD
- Sector
- Financial Services
- Industry
- Capital Markets
- ISIN
- Not available
- Market cap
- 251M
- P/E ratio
- 137.5
- Analyst target
- 3
- Dividend yield
- Not available
- Beta
- -3052.63
About
About OpGen Inc
CapForce Inc., a precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally. The company's products include Unyvero application cartridges, Unyvero systems, Acuitas AMR Gene Panel test products, and SARS CoV-2 test kits. It also provides laboratory services; collaboration services, including funded software arrangements; and license arrangements services. In addition, the company offers listing sponsorship and consultancy services. CapForce Inc. was formerly known as OpGen, Inc. and changed its name to CapForce Inc. in February 2026. CapForce Inc. was incorporated in 2001 and is based in Clarksburg, Maryland.
Research context
OpGen Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Financial Services
- Industry
- Capital Markets
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the OPGN discussion.
5 years, 6 months ago
OpGen, Inc is currently in a long term downtrend where the price is trading 2.7% below its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 9.6.
OpGen, Inc's total revenue rose by 64.8% to $1M since the same quarter in the previous year.
Its net income has increased by 99.7% to $-7K since the same quarter in the previous year.
Finally, its free cash flow fell by 102.5% to $-7M since the same quarter in the previous year.
Based on the above factors, OpGen, Inc gets an overall score of 3/5.